Table 1.
Patients’ baseline characteristics
| Patient number | 62 |
| Age (years) | 33.1 ± 10.3 |
| Gender (male) | 74.2 % (46/72) |
| Disease duration (months) | 96.0 (0.0–480.0) |
| Disease duration < 2 years | 32.3 % (20/62) |
| Disease location | |
| Ileo | 14.5 % (9/62) |
| Ileocolonic | 74.2 % (46/62) |
| Colonic | 11.3 % (7/62) |
| Surgery required | 62.9 % (39/63) |
| Extra fistula | 34.4 % (21/61) |
| Intra fistula | 8.2 % (5/61) |
| Perianal disease | 48.4 % (30/62) |
| Smoking | 17.3 % (9/52) |
| Concomitant use | |
| 5-Aminosalicylates | 91.9 % (57/62) |
| Steroids | 9.7 % (6/62) |
| Immunomodulators | 24.2 % (15/62) |
| Elemental diet | 62.9 % (39/62) |
| IFX experience | |
| Experience with IFX | 53.2 % (33/62) |
| Double dose | 33.3 % (11/33) |
| Duration of IFX use (months) | 19.0 (1.0–100) |
| Reason for switching | |
| PNR | 6.3 % (2/32) |
| SNR | 46.9 % (15/32) |
| Intolerance | 43.8 % (14/32) |
| Others | 3.1 % (1/32) |
| Baseline CDAI (points) | 185.1 ± 76.4 |
| Baseline CRP (mg/dL) | 0.74 (0.00–6.86) |
Parametric variables are shown as mean ± standard deviation or median (range)
IFX infliximab, PNR primary nonresponse, SNR secondary nonresponse, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein